Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tretinoin liposome
- Development stage
- Unknown
- Lead developer
- HighField Biopharmaceuticals
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
HF1K16 (tretinoin liposome) is an investigational pegylated liposome formulation of all-trans retinoic acid (ATRA, also known as tretinoin) developed by HighField Biopharmaceuticals. Unlike traditional applications of ATRA in acute promyelocytic leukemia (APL), HF1K16 is designed to target the immunosuppressive tumor microenvironment in solid tumors. It acts by infiltrating the tumor microenvironment and releasing ATRA, which binds to retinoic acid receptors (RARs) and promotes the differentiation and maturation of myeloid-derived suppressor cells (MDSCs) into functional antigen-presenting cells like dendritic cells. This depletion of MDSCs restores T-cell activity and remodels the tumor microenvironment from immunosuppressive to immunoreactive. HF1K16 is being evaluated in clinical trials for the treatment of advanced solid tumors, including recurrent glioma, pancreatic cancer, and non-small cell lung cancer.
- Other names
- all-trans retinoic acid liposome injectionliposomal tretinoinall-trans retinoic acid liposomeATRA liposome injectionliposomal all-trans retinoic acid
02
Targets
RARA (Retinoic acid receptor alpha)RARG (Retinoic acid receptor gamma)RARB (Retinoic acid receptor beta)
Beyond the preview
Go deeper on tretinoin liposome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tretinoin liposome.